ArticlePloS one2016
Large-Scale Recombinant Expression and Purification of Human Tyrosinase Suitable for Structural Studies.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 67 citations in OpenAlex.
- Molecular Targets in Modern Cosmetic Science.Molecules (Basel, Switzerland) · 2026Review
- In silico and in vitro exploration of a tyrosinase for biocatalytic production of catechols.FEBS open bio · 2026Article
- Structure-based design and evaluation of tyrosinase inhibitors targeting both human and mushroom isozymes.RSC medicinal chemistry · 2025Article
- Beyond traditional vaccines: Semi-purified low-pathogenic avian influenza H9N2 virus-like particles and their promise for broiler immunity.Veterinary world · 2024Article
- Discovery of Indole-Thiourea Derivatives as Tyrosinase Inhibitors: Synthesis, Biological Evaluation, Kinetic Studies, and In Silico Analysis.International journal of molecular sciences · 2024Article
- Molecular Modeling of the Multiple-Substrate Activity of the Human Recombinant Intra-Melanosomal Domain of Tyrosinase and Its OCA1B-Related Mutant Variant P406L.International journal of molecular sciences · 2024Article
- Tyrosinases: a family of copper-containing metalloenzymes.Chemtexts · 2024Article
- Biochemical Investigations of Five Recombinantly Expressed Tyrosinases Reveal Two Novel Mechanisms Impacting Carbon Storage in Wetland Ecosystems.Environmental science & technology · 2023Article
- Metabolic Pathway Reconstruction Indicates the Presence of Important Medicinal Compounds inInternational journal of molecular sciences · 2023Article
- Tyrosinase Inhibitors: A Perspective.Molecules (Basel, Switzerland) · 2023Review
- Structure-Guided Development of Bivalent Aptamers Blocking SARS-CoV-2 Infection.Molecules (Basel, Switzerland) · 2023Article
- Biochemical characterization of Dimocarpus longan polyphenol oxidase provides insights into its catalytic efficiency.Scientific reports · 2022Article
- The Novel Role of Tyrosinase Enzymes in the Storage of Globally Significant Amounts of Carbon in Wetland Ecosystems.Environmental science & technology · 2022Review
- Recycled Sericin Hydrolysates Modified by AlcalaseInternational journal of molecular sciences · 2022Article
- Cajanin Suppresses Melanin Synthesis through Modulating MITF in Human Melanin-Producing Cells.Molecules (Basel, Switzerland) · 2021Article
- Similar but Still Different: Which Amino Acid Residues Are Responsible for Varying Activities in Type-III Copper Enzymes?Chembiochem : a European journal of chemical biology · 2021Review
- Enhancing Catecholase Activity of a Recombinant Human Tyrosinase Through Multiple Strategies.Iranian journal of biotechnology · 2020Article
- Phenylthiourea Binding to Human Tyrosinase-Related Protein 1.International journal of molecular sciences · 2020Article
- FunctionalJournal of analytical & pharmaceutical research · 2020Article
- The TYRP1-mediated protection of human tyrosinase activity does not involve stable interactions of tyrosinase domains.Pigment cell & melanoma research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human tyrosinase (TYR) is a glycoprotein that initiates the first two reactions in the melanin biosynthesis pathway. Mutations in its encoding gene cause Oculocutaneous Albinism type I (OCA1), the most severe form of albinism, which is a group of autosomal recessive disorders characterized by reduced or absent production of melanin in skin, hair and eyes. Despite extensive structural and characterization studies of its homologues in lower eukaryotic organisms, the catalytic mechanism of human TYR and the molecular basis of OCA1 are largely unknown. In this work, we have carried out a large-scale recombinant expression of TYR that has enabled us to obtain high yields of pure and active protein, required for crystallization trials and screening of skin whitening agents, which is highly demanded in the cosmetic industry. Addition of an N-terminal honeybee melittin signal peptide for secretion of the produced protein into the (protein-free) medium, as well as a cleavable His-tag at the C-terminus, was crucial for increasing the yield of pure protein. We have successfully crystallized two TYR variants, in both glycosylated and deglycosylated forms, showing preliminary X-ray diffraction patterns at 3.5 Å resolution. Hence, we have established an expression and purification protocol suitable for the crystal structure determination of human TYR, which will give unique atomic insight into the nature and conformation of the residues that shape the substrate binding pocket that will ultimately lead to efficient compound design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.